@article {PALMISCIANO3251, author = {PAOLO PALMISCIANO and ANDREW L. CHEN and MAYUR SHARMA and OTHMAN BIN-ALAMER and GIANLUCA FERINI and GIUSEPPE E. UMANA and SALAH G. AOUN and ALI S. HAIDER}, title = {Intradural Extramedullary Spinal Metastases from Non-neurogenic Primary Tumors: A Systematic Review}, volume = {42}, number = {7}, pages = {3251--3259}, year = {2022}, doi = {10.21873/anticanres.15814}, publisher = {International Institute of Anticancer Research}, abstract = {Background/Aim: Intradural extramedullary spinal metastases (IESMs) may severely affect quality-of-life of oncological patients. Several treatments are available but their impact on prognosis is unclear. We systematically reviewed the literature on IESMs of non-neurogenic origin. Materials and Methods: PubMed, Ovid EMBASE, Scopus, and Web-of-Science were screened to include articles reporting patients with IESMs from non-neurogenic primary tumors. Clinico-radiological presentation, treatments, and outcomes were analyzed. Results: We included 51 articles encompassing 130 patients of a median age of 62 years (range=32-91 years). The most common primary neoplasms were pulmonary (26.2\%), renal (20\%), and breast (13.8\%) carcinomas. Median time interval from primary tumor to IESMs was 18 months (range=0-240 months). The most common symptoms were sensory (58.3\%) and motor (54.2\%) deficits. Acute cauda equina syndrome was reported in 29 patients (37.7\%). Lesions were diagnosed at magnetic resonance imaging (93.3\%), myelography (25\%), or computed tomography (16.7\%). All patients underwent decompressive laminectomy with tumor resection, partial (54.6\%) more frequently than complete (43.1\%). Adjuvant radiation (67.5\%) and/or systemic (13.3\%) therapies were administered. After treatment, most patients had symptom improvement (70.8\%) and optimal radiological response (64.2\%). Four patients experienced IESMs recurrences (3.1\%) with median local tumor control of 14.5 months (range=0.1-36 months). Deaths occurred in 50\% of patients, with median overall survival of 6.7 months (range=0.1-108 months). Conclusion: Patients with IESMs have significant tumor burden with poor prognoses. Resection and locoregional radiation may offer favorable clinico-radiological responses but are limited in achieving optimal local control and survival.}, issn = {0250-7005}, URL = {https://ar.iiarjournals.org/content/42/7/3251}, eprint = {https://ar.iiarjournals.org/content/42/7/3251.full.pdf}, journal = {Anticancer Research} }